DRL

At 6:36 AM, GIFT Nifty futures were up 19 points, trading at 24,828.50 levels, indicating a higher start for the day.

For the full year 2022-23, DRL's revenues were up 15 percent to Rs 24,587.9 crore while the PAT grew by 91 percent to Rs 4,506.7 crore

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday

US price erosion, India growth trends would be keenly tracked

Booster shot with Sputnik trials may also begin

We're seeing noticeable traction in the banking pack and Federal Bank has recently witnessed a breakout from a consolidation range

The recovery officer of Debt Recovery Tribunal (DRT) on Tuesday offloaded shares worth Rs 50 lakh of McDowell Holdings Ltd through an open market transaction

JSPL expects to conclude the deal to sell its 96.42 per cent stake in its arm Jindal Power for Rs 7,401 crore to a promoters-owned firm Worldone by this year end

A clear breakdown on price action and chart patterns may lead to slide in these stocks

Pharma major Dr Reddy's Laboratories (DRL) expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said

Jaguar Land Rover's retail sales fell 9 per cent YoY to 1,28,469 units in the October-December quarter

Drug to be imported from Japan for time being, India manufacturing to start soon

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets